Skip to main content
SpringerLink
Log in

ASO Author Reflections: mLST8 is a Prognostic Biomarker and Involved in Tumor Progression in Hepatocellular Carcinoma

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960–76.

    Article  CAS  Google Scholar 

  2. Yu XN, Chen H, Liu TT, Wu J, Zhu JM, Shen XZ. Targeting the mTOR regulatory network in hepatocellular carcinoma: are we making headway? Biochim Biophys Acta Rev Cancer. 2019;1871(2):379–91.

    Article  CAS  Google Scholar 

  3. Jiang XM, Yu XN, Huang RZ, et al. Prognostic significance of eukaryotic initiation factor 4E in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2016;142(11):2309–17.

    Article  CAS  Google Scholar 

  4. Yu X-N, Zhang G-C, Sun J-L, et al. Enhanced mLST8 expression correlates with tumor progression in hepatocellular carcinoma. Ann Surg Oncol. (2020). https://doi.org/10.1245/s10434-020-08263-6.

    Article  PubMed  Google Scholar 

  5. Guertin DA, Stevens DM, Thoreen CC, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 2006;11(6):859–71.

    Article  CAS  Google Scholar 

  6. Hwang Y, Kim LC, Song W, Edwards DN, Cook RS, Chen J. Disruption of scaffolding function of mLST8 selectively inhibits mTORC2 assembly and function and suppresses mTORC2-dependent tumor growth in vivo. Cancer Res. 2019;79:3178–84.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China

    Xiang-Nan Yu MD, Xi-Zhong Shen MD, PHD & Ji-Min Zhu MD, PHD

  2. Department of Severe Hepatitis, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China

    Hong-Ying Guo MD

  3. Shanghai Institute of Liver Disease, Shanghai, China

    Xiang-Nan Yu MD, Xi-Zhong Shen MD, PHD & Ji-Min Zhu MD, PHD

  4. Key Laboratory of Medical Molecular Virology, Shanghai Medical College of Fudan University, Shanghai, China

    Xi-Zhong Shen MD, PHD

Authors
  1. Xiang-Nan Yu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xi-Zhong Shen MD, PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong-Ying Guo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ji-Min Zhu MD, PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hong-Ying Guo MD or Ji-Min Zhu MD, PHD.

Ethics declarations

Disclosure

There are no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, XN., Shen, XZ., Guo, HY. et al. ASO Author Reflections: mLST8 is a Prognostic Biomarker and Involved in Tumor Progression in Hepatocellular Carcinoma. Ann Surg Oncol 27, 1558–1559 (2020). https://doi.org/10.1245/s10434-020-08275-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-020-08275-2

Search

Navigation